TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Dating Sites: Best, Worst & Weirdest
OPINION

Visa Insider Buys $400K Worth

  • By Jonathan Moreland
  • May 6, 2009 9:48 AM EDT
Dating Sites: Best, Worst & Weirdest
OPINION

Heartland Payment Chairman Sells Stock

  • By Jonathan Moreland
  • Apr 22, 2009 10:02 AM EDT
Dating Sites: Best, Worst & Weirdest
OPINION

JPMorgan Insider Sells $1.2M Worth

  • By Jonathan Moreland
  • Apr 20, 2009 9:30 AM EDT
Dating Sites: Best, Worst & Weirdest
OPINION

Shutterfly Insider Sells $580,000 Worth

  • By Jonathan Moreland
  • Apr 9, 2009 9:28 AM EDT
STOCKS

Biotech Stock Mailbag: Fans Rally 'Round Arena

  • By Adam Feuerstein
  • Mar 27, 2009 7:59 AM EDT
STOCKS

Cell Genesys' Net Loss Reduces

  • By TheStreet Ratings
  • Mar 10, 2009 1:11 PM EDT
STOCKS

Biotech Scorecard: My Best and Worst Calls

  • By Adam Feuerstein
  • Jan 2, 2009 6:59 AM EST
Galena Craters on Breast Cancer Vaccine Study Failure
STOCKS

Biotech Mailbag 2008 Review

  • By Adam Feuerstein
  • Dec 29, 2008 12:20 PM EST
Germany Slaps PTC Therapeutics With Big Drug Price Cut
STOCKS

Elan's Martin Named Worst Biotech CEO of '08

  • By Adam Feuerstein
  • Dec 11, 2008 10:44 AM EST
INVESTING

Biotech Stock-Picking: Incyte, Celgene

  • By TSC Staff
  • Oct 27, 2008 6:37 PM EDT
Duchenne Drug Developer (Not Sarepta) Hit With Lengthy FDA Delay
STOCKS

Biotech Mailbag: Lessons From Clinical Trials

  • By Adam Feuerstein
  • Oct 24, 2008 4:10 PM EDT
Dating Sites: Best, Worst & Weirdest
INVESTING

Health Winners & Losers: Gilead

  • By Elizabeth Trotta
  • Oct 16, 2008 3:31 PM EDT
Galena Craters on Breast Cancer Vaccine Study Failure
STOCKS

Cell Genesys Halts Second GVAX Trial

  • By Elizabeth Trotta
  • Oct 16, 2008 12:50 PM EDT
Germany Slaps PTC Therapeutics With Big Drug Price Cut
STOCKS

Biotech Mailbag: Avoid Nuvelo-ARCA Merger

  • By Adam Feuerstein
  • Sep 26, 2008 11:05 AM EDT
Chiasma's Acromegaly Drug Headed for FDA Rejection, Investor Says
STOCKS

Biotech Mailbag: Epix Pharmaceuticals

  • By Adam Feuerstein
  • Sep 5, 2008 6:59 AM EDT
Dating Sites: Best, Worst & Weirdest
INVESTING

Three Biotech Stocks That Could Double

  • By James Altucher
  • Sep 2, 2008 1:54 PM EDT
Dating Sites: Best, Worst & Weirdest
INVESTING

Health Winners & Losers: Amylin

  • By Elizabeth Trotta
  • Aug 28, 2008 4:33 PM EDT
Dating Sites: Best, Worst & Weirdest
INVESTING

Health Winners & Losers: Cell Genesys

  • By Elizabeth Trotta
  • Aug 27, 2008 4:55 PM EDT
STOCKS

Cell Genesys Ends Prostate Cancer Study

  • By Elizabeth Trotta
  • Aug 27, 2008 10:52 AM EDT
Ziopharm Co-Dependency Spirals Down in Amended Intrexon Deal
STOCKS

Biotech-Stock Mailbag: Amylin

  • By Adam Feuerstein
  • Aug 22, 2008 1:20 PM EDT
Galena Craters on Breast Cancer Vaccine Study Failure
STOCKS

Feuerstein's Biotech-Stock Mailbag

  • By Adam Feuerstein
  • May 30, 2008 10:36 AM EDT
STOCKS

Cell Genesys Issues Stock in Private Placement

  • By Elizabeth Trotta
  • May 12, 2008 10:50 AM EDT
STOCKS

Japan's Takeda Will Pay $9B for Millennium

  • By Adam Feuerstein
  • Apr 10, 2008 7:05 AM EDT
INVESTING

Tuesday's Winners & Losers: Cell Genesys

  • By TSC Staff
  • Apr 1, 2008 4:32 PM EDT
Dating Sites: Best, Worst & Weirdest
INVESTING

Tuesday's Health Winners & Losers

  • By Elizabeth Trotta
  • Apr 1, 2008 4:08 PM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.